Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background of the study:
Functional constipation (FC) is common in children and poses a significant burden to patients, their families and the healthcare system. Pharmacological treatment mainly consists of oral osmotic laxatives. However, poor adherence to oral laxatives is known to be a common problem and patients often remain symptomatic despite pharmacological treatment. Many parents seek help in the form of complementary and integrative medicine. Acupuncture has been shown to relieve symptoms in adults with FC. However, published studies in children with FC are scarce and have important limitations.
Objective of the study:
To evaluate the feasibility, safety and potential efficacy of acupuncture in children with FC. The results of this study will be used to design a future randomized controlled trial (RCT).
Study design:
A prospective, non-randomized, multicenter, open-label pilot study.
Intervention: Children will receive 8 acupuncture sessions during 10 weeks (1 session per week during 6 weeks, followed by 1 session every other week during 4 weeks). Concurrent pharmacological treatment with polyethylene glycol ≥ 0.2 g/kg/day will be maintained as initiated prior to participation in the study.
Study population:
18 children (6-18 years old) with FC according to the Rome IV criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single-arm study. The intervention consists of acupuncture treatments | Other | This is an open-label, non-randomized single-arm study. The intervention consists of acupuncture (see description under intervention). Throughout the study duration, participants will maintain their therapeutic recommendations related to treating constipation (PEG at the dosage prior to entering the study, minimum of 0.2 g/kg/day, education and non-pharmacological advice as previously described by the medical team in charge). Initiation of new treatments for FC or increasing the dosage of PEG is not allowed during the intervention period. Decreasing the dosage of PEG is allowed if instructed by the treating physician and will be documented. After the last acupuncture session, if the patient requires an increase in the dosage of PEG, this is allowed during the follow-up period and will be documented. As per current treatment guidelines, participants are allowed to use escape medication (bisacodyl or enemas) after 72 hours without defecation or when their symptoms become intolerable. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acupuncture treatment | Other | Children will receive 8 acupuncture sessions during 10 weeks (1 session per week during 6 weeks, followed by 1 session every other week during 4 weeks). At each acupuncture session, the acupuncturist records the patient's bowel habits, gastrointestinal symptoms and the use of escape medication during the period between sessions. After 3, 6 and 8 acupuncture treatments respectively, patients will visit the research team after they receive acupuncture to evaluate adverse events. After completion of these 10 weeks, an acupuncture-free follow-up period of 4 weeks commences. The follow-up period will be used to investigate if and how long effects of the intervention will persist. During the intervention period and the follow-up period, escape medication (bisacodyl or enemas) is allowed under the same conditions as during the run-in period. |
| Measure | Description | Time Frame |
|---|---|---|
| Primary outcome measure: feasibility | The primary endpoint is feasibility: a future RCT using this same intervention protocol will be deemed feasible if the pilot study renders an attrition rate ≥70% (i.e. ≥70% of patients completing the pilot study while attending ≥75% of scheduled acupuncture sessions). | From enrollment until the end of the intervention period (at 10 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary outcome measure: Feasibility | Secondary endpoints to determine feasibility include consent rate, patient and parent satisfaction with acupuncture treatment (measured at t=6, t=10 and t=14 [5-point-Likert scale]) and assessment of required personnel capacity for a future RCT | From enrollment to the end of intervention (week 10) and follow-up (week 14) |
Not provided
Inclusion Criteria:
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
6-18 years of age
meet the modified Rome IV criteria for FC (defined as meeting at least two of the following criteria during the 2-week run-in period despite receiving treatment with PEG with a minimum dose of 0.2 g/kg/day):
Insufficient symptom management despite at least three months of medical management (including education, non-pharmacological advice and laxatives) by a physician. Insufficient symptom management is defined as the presence of at least one of the Rome IV criteria for FC despite medical management by a physician.
are treated with PEG with a minimum dose of 0.2 g/kg/day for a minimum of 1 month prior to inclusion in the study
Written informed consent obtained from parents or guardians and all children ≥12 years.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41218934 | Derived | Bloem MN, Baaleman DF, Koppen IJN, Vlieger AM, de Lorijn F, Birch S, Nieuwdorp M, Benninga MA. Prospective, non-randomised, open-label pilot trial assessing feasibility, safety and treatment success of acupuncture in children with functional constipation: ACU-PILOT study protocol. BMJ Open. 2025 Nov 11;15(11):e109425. doi: 10.1136/bmjopen-2025-109425. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015670 | Acupuncture Therapy |
| ID | Term |
|---|---|
| D000529 | Complementary Therapies |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Secondary Outcome Measure: Safety (assessment of adverse events) | The occurrence of adverse events (AE) is assessed at each research nurse visit (t=3, t=6, t=10, t=14). The occurrence of the following pre-determined adverse events are assessed: needle-related pain, local redness/irritation, hematomas, headache, fainting/syncope, sedation, neuropathy. For each patient-reported AE, severity (mild, moderate, or severe) and relation to acupuncture treatment (unrelated or possibly, probably, or definitely related) are determined. | From first acupuncture treatment until last treatment (week 10) and after follow-up (week 14) |
| Secondary Outcome Measure: Efficacy | The endpoint for efficacy is treatment success, based on the Rome IV criteria (Table 1): a child who fulfils the Rome IV criteria for FC prior to enrolment into the trial and no longer fulfils the Rome IV criteria at the end of the trial period is considered successfully treated. The endpoints, including quality of life and school absence, are based on a previously published core outcome set and include:
| From start of intervention until end of intervention (at week 10 and at follow-up (at week 14) |